Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Annexon adds $100m
The round pushed the overall funding for the Novartis-backed autoimmune and neurodegenerative disorder drug developer past $250m.
Bolt latches onto series C financing
Novo, Pfizer and Nan Fung helped provide $93.5m for the cancer treatment developer as it advances its lead product candidate towards the clinic.
CapitalBio Technology cashes $113m
Sinopec Capital and Meinian Onehealth both invested in the biotech research product maker as it prepares for an initial public offering.
Goldfinch Bio holds on to $100m
Existing backer Gilead Sciences returned for a series B round that boosted the kidney disease therapy developer's total funding to $160m.
Genor Biopharma generates filing for $320m IPO
The autoimmune disease and cancer drug developer plans to float in Hong Kong having recently secured $160m from investors including a Charoen Pokphand-backed fund.
Novo gets in Freeline for $120m round
The pharmaceutical company co-led a series C round for AAV gene therapy developer Freeline that took its total funding to $275m.
Berkeley Lights works towards $100m IPO
The cell biology technology provider, which counts Nikon and Varian Medical among its investors, has raised about $215m in venture funding.
Pandion plans $75m initial public offering
SR One and Roche Venture Fund-backed Pandion Therapeutics will use the proceeds from the offering to advance a lead drug candidate for ulcerative colitis.

Other News

Simcha shakes down $25m
Wuxi AppTec and Pfizer contributed to a series A round that will support progress of Simcha Therapeutics' immuno-oncology treatments toward clinical trials.
Akouos acquires $213m in initial public offering
The hearing loss treatment developer, which counts Novartis Venture Fund and Partners Innovation Fund as investors, floated above its range.
Fusion Pharma fetches $213m in IPO
Johnson & Johnson and Varian Medical exited the cancer radiotherapy developer in an upsized initial public offering after $158m in funding.
Poseida slots in $110m ahead of IPO
Novartis and Transposagen-backed gene and cell therapy developer Poseida Therapeutics closed the series D round two days after filing to go public.
Enterome enters series E stage
Nestlé Health Science and Takeda participated in a series E round for Enterome, which received $52.6m in equity and debt financing through the deal.
Artiva arrives with $78m
Artiva Biotherapeutics is leveraging GC LabCell’s cell therapy technology to target cancer, and has raised series A funding from backers including the latter.

Editor's Picks

Forma Therapeutics finishes IPO at $319m
Forma Therapeutics, whose investors include Eli Lilly and Novartis, has closed its IPO after seeing its shares double in price.
Forma forces its way to $278m IPO
The Novartis and Eli Lilly-backed cancer and haematologic disease drug developer will go public today having expanded the size of its offering.
Avidity achieves $259m initial public offering
Muscle disease drug developer Avidity, which counts Eli Lilly, EMS, Takeda and ST Pharm as investors, went public in a significantly upized IPO.
Oric ordains $120m initial public offering
Cancer therapy developer Oric, whose backers include Memorial Sloan, Taiho and Hartford HealthCare, floated at the top of its range in an expanded IPO.
test reg